Canaccord Genuity Reiterates a 'Buy' on Spectranetics (SPNC); Positive Affimation After Meeting with Mgmt

March 19, 2012 8:37 AM EDT Send to a Friend
Get Alerts SPNC Hot Sheet
Price: $34.32 -2.36%

Rating Summary:
    8 Buy, 1 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade SPNC Now!
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Spectranetics (NASDAQ: SPNC) price target raised from $12 to $14.50.

Analyst, Jason R. Mills, said, "We spent time last week with SPNC management as well as world-renowned electrophysiologist (EP) Dr. Larry Epstein (Brigham & Women’s Hospital-Boston) during a non-deal road-show on the East Coast. We came away from these discussions even more confident in the company’s growth prospects in both lead management and peripheral vascular disease. We raise our forward revenue estimates and think the multiple will expand as revenue accelerates."

"Our new, modestly higher 2012 and 2013 revenue estimates of $136.2M and $147.6M (from $135.5M and $145.7M) conservatively reflect Y/Y growth of 7.0% and 8.4%, respectively."

For an analyst ratings summary and ratings history on Spectranetics click here. For more ratings news on Spectranetics click here.

Shares of Spectranetics closed at $9.56 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Add Your Comment